Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response

Authors

  • Stacy Moulder MD, MSCI,

    Corresponding author
    1. Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    2. Department of Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Breast Medical Oncology, Unit 1354, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., PO Box 301438, Houston, TX 77030===

    Search for more papers by this author
    • Fax: (713) 794-4385

    • Dr. Moulder received a speaker's honorarium from Eli Lilly.

  • Nickola Valkov MD, PhD,

    1. Department of Pathology and Cell Biology, University of South Florida, Tampa, Florida
    Search for more papers by this author
  • Anthony Neuger MS,

    1. Clinical Trials Laboratory Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Jimin Choi PhD,

    1. Biostatistics Core Group, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Ji Hyun Lee DrPH,

    1. Biostatistics Core Group, Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Susan Minton DO,

    1. Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Pamela Munster MD,

    1. Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Jana Gump,

    1. Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Mira Lacevic MD,

    1. Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Richard Lush PhD,

    1. Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author
  • Dan Sullivan MD

    1. Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Search for more papers by this author

Abstract

BACKGROUND.

Gemcitabine incorporation into DNA enhances cleavage complexes in vitro when combined with topoisomerase I inhibitors and demonstrates synergy in cancer cells when given with irinotecan. Topoisomerase I inhibitors require that topoisomerase I interacts with DNA to exert activity.

METHODS.

Patients who had received previous anthracycline therapy or were not candidates for anthracycline therapy received gemcitabine at a dose of 1000 mg/m2 intravenously over 30 minutes followed by irinotecan at a dose of 100 mg/m2 over 90 minutes on Days 1 and 8 of a 21-day cycle. The primary endpoint was improvement in response from that historically observed with gemcitabine (from 25% to 45%) as measured by Response Evaluation Criteria in Solid Tumors. Correlative studies included characterization of cellular levels and nuclear distribution of topoisomerase I and pharmacokinetic analysis of gemcitabine and irinotecan.

RESULTS.

Forty-nine patients were assessed for response. The response rate was approximately 25% (all partial responses [PRs], 12 patients; 95% confidence interval [95% CI], 13-39). Six patients had stable disease (SD) for ≥6 months for a clinical benefit rate (PR + SD) of 39%. The median time to disease progression was 3.7 months (95% CI, 2.5 months-4.6 months), and median survival was 11.6 months (95% CI, 8.9 months-15 months). Toxicities included neutropenia, nausea, and vomiting. Seven of 9 tissue biopsies were assessable for topoisomerase I. Tumors with the 2 lowest nuclear to cytoplasmic ratios demonstrated no response to irinotecan.

CONCLUSIONS.

Gemcitabine and irinotecan are active in metastatic breast cancer, but response did not meet predetermined response parameters, and the null hypothesis was accepted. Topoisomerase I localization can be measured in metastatic breast cancer. Further validation is needed to determine whether this assay can predict response. Cancer 2008. © 2008 American Cancer Society.

Ancillary